AC-003
Acute Graft-Versus-Host Disease (aGVHD)
Phase 1bActive; FDA Orphan Drug Designation
Key Facts
Indication
Acute Graft-Versus-Host Disease (aGVHD)
Phase
Phase 1b
Status
Active; FDA Orphan Drug Designation
Company
About Accro Bioscience
Clinical-stage biotech developing novel therapeutics targeting regulated cell death mechanisms for immune-mediated diseases and cancer.
View full company profileTherapeutic Areas
Other Acute Graft-Versus-Host Disease (aGVHD) Drugs
| Drug | Company | Phase |
|---|---|---|
| MaaT013 | MaaT Pharma | Phase 3 |
| Tregalizumab | CD4 Therapeutics | Phase 2 |
| ABCB5+ MSCs | RHEACELL | Pre-clinical development |
| Apraglutide | Ironwood Pharmaceuticals | Phase 2 |
| Itolizumab (EQ001) | Equillium | Phase 1b |